Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...
AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...
The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...
AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...
Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody ...
Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...
In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...
In epidemiological, genetic, and intervention studies, mixed dyslipidaemia, characterised by elevated concentrations of total ...
Coronary artery disease has long been understood through the paradigm of epicardial coronary artery obstruction, causing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback